Introduction Recent advances in molecular understanding of pathophysiological processes continue to fuel great interest in clinical exploration of gene therapy. Increased safety concerns associated with highly effective viral vectors mandate development of novel nonviral gene carriers in order to revolutionize clinical management of debilitation genetic disorders such as cystic fibrosis, diabetes,
No takes yet. Share an insight, caveat, or question.
Ellah et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: